tbuckley/cabot-search huggingface dataset:
MURMURS, SUDDEN DEATH, AND FAMILIAL HEART DISEASE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PRESS AND QUACK ADVERTISEMENTS.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Molecular Immunobiology of Complement Biosynthesis: A Model of Single-Cell Control of Effector-Inhibitor Balance
Authors: D. Perlmutter
Journal: Annual Review of Immunology (1986)

Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression, ...Read More
Masaru Ishihara
Authors: R.R. Suskind
Journal: British Journal of Dermatology (1987)

Journal Article Masaru Ishihara Get access R.R. Suskind R.R. Suskind Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 116, Issue 2, 1 February 1987, Page 275, https://doi.org/10.1111/j.1365-2133.1987.tb05828.x Published: 01 February 1987
Recombinant plasminogen agent continues to show promise in trials
Authors: M. F. Goldsmith
Journal: JAMA (1985)

Results of the first multicenter clinical trial of recombinant human tissue-type plasminogen activator have taken the thrombolytic protein "out of the speculative pilot phase and put it into the clinically useful phase." That is the assessment of Burton E. Sobel, MD, director of cardiology at Washington University School of Medicine-Barnes Hospital Medical Center, St Louis, one of the three trial locations (<i>JAMA</i>[MEDICAL NEWS] 1984;251:1651-1652). Speaking at the annual meeting of the American Heart Association in Miami Beach, Sobel said he considers the successful trial—in which intravenously injected recombinant human tissue-type plasminogen activator opened coronary arteries in 35 of 50 patients with transmural infarctions and angiographically documented coronary occlusions—"a reason for tremendous excitement." Genentech Inc, the South San Francisco, Calif, genetic engineering firm that produces recombinant human tissue-type plasminogen activator in this country, he added, "has taken a [sparsely occurring native] molecule with great potential and produced it for practical
Does myocardial perfusion SPECT affect the frequency of normal coronary angiograms in men and women? Howard C. Lewin, Pamela A. Ivey, Clara Lu Brandt, C. Noel Bairey Merz, Enrique F. Schisterman, Sean W. Hayes, John D. Friedman, Daniel S. Berman. Cedars-Sinai Medical Center, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
Legionnaires' Disease
Authors: Kumarapuram K. Venkatachalam
Journal: JAMA (1979)

LEGIONNAIRES' disease can occur in both epidemic and sporadic forms, and the clinical manifestations may range from asymptomatic infection to fulminant pneumonia.<sup>1</sup>We report a case of lung abscess from the Legionnaires' bacterium occurring in a renal homograft recipient. <h3>Report of a Case</h3> A 32-year-old woman who had been receiving long-term hemodialysis for four years for chronic renal failure secondary to nephrosclerosis received her second cadaver kidney transplant in November 1977. Immunosuppression consisted initially of azathioprine, 2.5 mg/kg of body weight, and methylprednisolone, 1.2 mg/kg of body weight. Four courses of antirejection therapy, each consisting of 1 g of methylprednisolone intravenously daily for three days, were given during a one-month period. The kidney was removed 34 days after transplantation, due to irreversible rejection. Azathioprine therapy was discontinued, and the dosage of methylprednisolone was halved to 24 mg/day on the day of transplant nephrectomy. She had been afebrile during the
Letter: Women doctors in the N.H.S.
Authors: I Gordon-Smith, J Hickman, L Prescorr
Journal: BMJ (1975)

It is our ontention that, though there is some evidence that venous thrombosis after operation and impaired fibrinolysis are re- lated, the link is still only tenuous and un- likely to be of major importance.This would explain on the one hand why prophylactic regimens sudh as phenformin and ethyl- oestrenol (which increase fibrinolytic activity) have not been effective in preventing postoperative venous thuombosis7 and on the other hand why a powerful fibrinolytic in- hibitor E-amnnoaproic acid, admiiinistered during the perioperative period was not associated with an increased incidence of deep vein xirombosis.8-We are, etc.,
Genito-Urinary Diagnosis and Therapy for Urologists and General Practitioners.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Lipid Composition of Mitochondrial and Microsomal Fractions of Human Myocardial Homogenates
Authors: J. Gloster, P. Harris
Journal: Cardiovascular Research (1969)

Biopsy specimens of human left atrium have been subjected to homogenization and mitochondrial and microsomal fractions separated by differential ultracentrifugation. The lipid composition of each fraction has been analysed by thin layer chromatography and the fatty acid spectrum of each lipid class analysed by gas liquid chromatography.
Highlights
Journal: JAMA Oncology (2017)

This meta-analysis addressed the utility of minimal residual disease (MRD) assessment in predicting survival outcomes in patients with multiple myeloma.In a Medline search 1990 to 2016, MRD-negative status following treatment was associated with a signifi cant improvement in progression-free and overall survival.Munshi et al note that MRD assessment after initial treatment could be a useful surrogate end point for progression-free and/or overall survival in clinical trials.Gormley et al provide an Editorial.
MODIFICATION OF THE "RED CROSS OF GENEVA" AS THE PROPOSED SYMBOL OF MEDICINE.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?
Authors: Hui-li Wong, Kathryn M Field, Jeanne Tie, Suzanne Kosmider, Jeremy David Shapiro, Joseph J McKendrick, Phillip Parente, Lara Rachel Lipton, Desmond Yip, Sagun Parakh, Louise M. Nott, Peter Gibbs
Journal: Journal of Clinical Oncology (2013)

534 Background: The management of patients with poor performance status (PS) remains challenging in the absence of data on optimal treatment. Here we assessed the treatment and outcomes of patients with metastatic colorectal cancer (mCRC) with poor Eastern Cooperative Oncology Group (ECOG) PS (≥ 2) in routine clinical care. Methods: Analysis of patients prospectively entered onto the TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) database, a clinician-designed initiative to collect comprehensive data on consecutive patients with mCRC from sites across Australia. Data collection commenced in July 2009 and is ongoing at 14 participating public and private centres. Results: Of the 679 patients entered, 129 (19.0%) had an ECOG PS ≥ 2. In total, 77 (11.3%) were PS 2, 41 (6.0%) PS 3 and 11 (1.6%) PS 4. Chemotherapy was administered to 55 (71.4%) PS 2 and 15 (36.6%) PS 3 patients, with none of the PS 4 patients being treated. Overall, poor PS patients were significantly less likely to receive any chemotherapy compared to their good PS (PS 0-1) counterparts (55.0% versus 86.8%, p&lt;0.0001) and, when chemotherapy was given, significantly less likely to receive combination chemotherapy (38.0% vs 71.6%, p&lt;0.0001) or bevacizumab (15.5% vs 46.9%, p&lt;0.0001). Overall survival (OS) was reduced with declining PS, with medians of 31.2, 9.0, 3.0 and 0.8 months for PS 0-1, 2, 3 and 4 patients respectively (p&lt;0.0001). Poor PS patients treated with chemotherapy had a better OS outcome (9.8 vs 4.1 months for untreated patients, p&lt;0.0001). At one and two years, 22 (31.4%) and 8 (11.4%) treated poor PS patients were alive. Conclusions: In routine practice many patients with a poor PS, particularly those that are PS 2, receive active treatment. Although overall survival for poor PS patients is poor, some patients appear to benefit from treatment. Further data analysis, particularly to define subsets that may benefit most from treatment, is planned as further sites around Australia contribute data to the project.
Should Physicians Have a Nursing Education?
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thirty-Sixth Annual Symposium on Fundamental Cancer Research
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Thirty-Sixth Annual Symposium on Fundamental Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 69, Issue 3, September 1982, Page 745, https://doi.org/10.1093/jnci/69.3.745-a Published: 01 September 1982
Experimental Pulmonary Emphysema in Dogs
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hereditary components in epileptic patients. Electroencephalogram family studies
Authors: E. Rodin
Journal: JAMA (1966)

The electroencephalograms of 80 families of epileptic patients were compared with those of 30 normal control families. Abnormal family EEGs were not only encountered in patients with centrencephalic seizures but also in patients with psychomotor epilepsy. One half of all patients with focal sharp wave or spike discharges were found to have another family member with an abnormal EEG. Abnormal family EEGs were more frequently encountered in female than in male patients. Mothers of epileptic patients had a significantly higher percentage of electroencephalographic abnormalities than fathers, regardless of the type of seizure the patient was experiencing. Patients whose seizures started between the ages of 6 and 15 years usually had a genetic component to their illness, as demonstrated by electroencephalographic abnormalities in one parent and at least one sibling.
In Reply:
Authors: James C. Yao
Journal: Journal of Clinical Oncology (2008)

does not hold true for metastatic rectal carcinoids and metastatic rectal adenocarcinomas. [3]] As pointed out by Yao et al, 1 analysis of data obtained from the Surveillance, Epidemiology, and End Results (SEER) registries likely underestimates the total number of patients with NETs.As only patients with (supposedly) malignant NETs are included in the SEER registries, many small benign-appearing NETs (ie, appendiceal tumors) likely are excluded from the SEER registries.Important to note, the distinction between benign and malignant behavior is often not possible for NETs at the time of diagnosis.The normal appearance of regional lymph nodes on radiological imaging does not exclude metastatic spread. 8Thus, a 6-mm-sized, well-differentiated carcinoid of the rectum with normal-appearing regional lymph nodes (on imaging) may be considered a benign-appearing rectal carcinoid.If lymph node dissection is performed and lymph node involvement is found histologically, the 6-mm-sized, well-differentiated rectal carcinoid (with preoperatively normal appearing lymph nodes on imaging) is postoperatively reclassified as a malignant carcinoid. 8 Therefore, the quality of the data on carcinoids of the SEER registries would be much improved if all NETs were registered.The currently available SEER data on carcinoids appears to be biased.The prevalence of rectal carcinoids in adults (mean/median age, 48.8 to 54 years) undergoing screening endoscopy is known to be 0.05% to 0.07%. [9][0][11] In 2006, 57.1% of US men and women age 50 years or older reported they had received at least one examination with flexible sigmoidoscopy or colonoscopy. 12 When considering that about 55 million US citizens have been scoped and on the basis of a prevalence rate of 0.05% to 0.07%, one would expect some 27,500 to 38,500 rectal carcinoids to have been diagnosed by screening endoscopy in the United States.Coincident with the implementation of colorectal cancer screening, overall 5-year-survival of patients with rectal carcinoid disease has increased steadily in the United States. 5Therefore, we should no longer regard rectal carcinoids that are detected by screening endoscopy as incidentally identified lesions.The early detection of colorectal carcinoids is one of the aims of endoscopic screening of the colorectum.The observed shift to more localized tumor stages at the time of diagnosis of NETs argues for the effectiveness of endoscopic screening.
P1.01-15 Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426
Authors: K. Naoki, Y. Ichikawa, A. Bessho, S. Hosokawa, T. Shimokawa, M. Yomota, Y. Hosomi, S. Otani, Y. Nakahara, S. Iwasawa, T. Tokito, N. Seki, H. Okamoto
Journal: Journal of Thoracic Oncology (2019)
Reversible suprasellar pituitary mass secondary to hypothyroidism
Authors: J. A. Atchison
Journal: JAMA (1989)

Sellar enlargement and suprasellar extension of a pituitary mass, demonstrated by magnetic resonance imaging or computed tomographic scanning in three children with primary hypothyroidism, resolved after treatment with levothyroxine sodium. This condition, a logical consequence of the pathogenesis of primary hypothyroidism, must be considered in patients with pituitary and suprasellar masses. (<i>JAMA</i>. 1989;262:3175-3177)
Operable breast carcinoma associated with refractory anemia
Authors: A. R. Soble
Journal: JAMA (1976)

A WOMAN with undiagnosable anemia was cured when a localized breast cancer, necrotic and surrounded by an inflammatory reaction was removed by radical mastectomy. <h3>Report of a Case</h3> A 47-year-old woman was referred for diagnosis of fatigue and anemia of approximately one year's duration. She had been treated with cyanocobalamin injections and oral iron therapy, without hematological response. Except for cholecystectomy and surgery for anal fistula, her health had been good. There was no history of drug ingestion, except for the hematinics, or toxic exposure. Family history was negative for hematolotic disease, and there was no history or evidence of gastrointestinal bleeding or menorrhagia. Results of physical examination were normal except for the findings of pallor and a firm 4-cm mass in the upper outer quadrant of the right breast. Results of laboratory studies included a red blood cell (RBC) count of 4.22 million/cu mm, a hemoglobin level of 8.7
Erratum
Authors: M Eng, F Ross, L Eng, C Rowntree, W Scott, M Toronto, C Eng, L Lond, G Thompson, St Mary's Hospital, C Walters, B Middleton, W Wiley, J Leech, J Rolmes, J Nichol- Son, E Collen, H Boxwell, H O', R May, T Clampett, M Farquharson, M Greenwood
Journal: BMJ (1903)
In Reply
Authors: Sankha S. Mitra, Kannon Nathan, Richard Simcock, Anthony Chalmers
Journal: Journal of Clinical Oncology (2007)

IN REPLY:We would like to commend Lacouture et al for a plausible explanation for the absence of the erlotinib rash on the skin at the site of previous radiotherapy in our patient. 1This can be confirmed by biopsies of the irradiated and normal skin in the same patient.Epidermal growth factor receptor (EGFR) expression as measured by immunohistochemistry in the irradiated skin should be reduced or absent with evidence of apoptosis and fibrosis.In a similar experience to the authors' regarding radiosensitisation of erlotinib, our patient also had a more severe papulopustular rash over the scalp, as he had whole-brain radiotherapy for brain metastases concurrently with erlotinib at 150 mg a day, administered as systemic therapy at that time.Because his intracranial disease is exceptionally well controlled for more than 18 months now, we suggest more clinical trials of EGFR inhibitors in combination with radiation, as it has exciting possibilities to optimize cancer therapy.Theoretically, radiation-induced phosphorylation of EGFR remains a proposed mechanism for accelerated repopulation during radiother-apy. 2 The knowledge of temporal dependence of the effect of radiation on erlotinib-induced rash will hopefully stimulate further research in this field.